Verbatim response from ChatGPT
Short answer
- Many people lose noticeable weight fairly quickly on GLP‑1 receptor agonists — often a few percent of body weight within the first 2–3 months and larger losses across 6–12 months. Typical clinical‑trial averages are roughly 10–20% body weight after ~6–12 months depending on the drug and dose.
- Weight loss is usually sustained while you keep taking the medicine, but if you stop the drug much of the lost weight is likely to return unless you maintain strong diet/exercise/behavior changes or use another long‑term strategy.
What to expect (typical ranges)
- Semaglutide (brand names: Wegovy for weight management; Ozempic/Rybelsus for diabetes at different formulations/doses): in obesity trials, semaglutide 2.4 mg produced mean weight loss on the order of ~10–15% of baseline body weight over ~9–12 months (some people lost more, some less).
- Tirzepatide (brand names: Zepbound approved for weight management; Mounjaro used for diabetes): in trials for obesity it produced larger average losses (often in the high‑teens to low‑20s percent range at the higher doses over ~9–12 months).
- Early phase: many people lose a disproportionate share of total loss in the first 3–6 months; the rate usually slows after that and you may hit a plateau.
Why results vary
- Starting weight and body composition, dose and how quickly it’s titrated, adherence, diet and physical activity, metabolic differences, and other medications or medical conditions all change how fast and how much you lose.
- Gastrointestinal side effects (nausea, reduced appetite) blunt calorie intake early on and contribute to faster initial loss for some people.
Is the loss sustainable?
- While you remain on a GLP‑1 at an effective dose and maintain healthy behaviors, weight loss is often maintained in clinical trials.
- Stopping the medication commonly leads to partial or full regain over months to a couple of years unless lifestyle changes (and sometimes other treatments) are used to preserve the loss. In other words, for many people this is a long‑term treatment like blood pressure or cholesterol medications.
- Combining GLP‑1 therapy with structured dietary support, physical activity, and behavioral therapy improves the odds of lasting benefit and may reduce regain if the drug is discontinued.
Safety and practical notes
- Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain; usually milder with slow dose escalation.
- Serious but uncommon issues: pancreatitis, gallbladder disease, and potential thyroid C‑cell tumor risk observed in rodents — GLP‑1s are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. Not recommended in pregnancy.
- Cost/coverage: Wegovy and Zepbound are approved for obesity but can be expensive; some insurers restrict coverage. Ozempic and Mounjaro are approved for diabetes but are sometimes used off‑label for weight.
- Always start and monitor these medicines with a clinician who can screen for contraindications and manage side effects and dose changes.
Next steps
- Talk with your prescriber about which option (semaglutide vs tirzepatide, dose, titration schedule) fits your health profile and goals.
- If you want, tell me your current weight and target and I can give an illustrative example of how much weight you might expect to lose in 3, 6, and 12 months based on typical trial averages.